| Metric | Value (₹ Cr) | Q4 FY25 |
|---|---|---|
| Revenue | 1.2K | 18.2% |
| Total Income | 1.2K | 18.1% |
| Expenditure | 1.0K | 15.7% |
| PBT | 171.88 | 70.9% |
| Net Profit | 153.58 | 79.5% |
| OPM | 19.70% | 3.14pp |
| NPM | 12.60% | 4.31pp |
| EPS | 2.72 | 71.1% |
Aster DM Healthcare Q4 FY26 Revenue up 18% to ₹1,182 Cr; Op. EBITDA up 31%
30 Apr 2026 · 30 Apr, 4:17 pm
Summary
Aster DM Healthcare reported a robust Q4 FY26 performance, with standalone revenues increasing by 18% year-on-year to INR 1,182 Cr. Operating EBITDA (excluding Kasaragod) saw a significant 31% growth to INR 253 Cr, pushing margins to 21.7% from 19.3% in the prior year. Normalised Profit After Tax (excluding Kasaragod) surged by 45% YoY to INR 153 Cr. On a combined proforma basis with Quality Care India Limited, revenues reached INR 2,361 Cr, and Operating EBITDA grew 25% to INR 517 Cr, further bolstered by overwhelming shareholder approval for the merger.
Key Highlights
- 1
Revenue for Aster DM Healthcare (standalone) in Q4 FY26 grew 18% YoY to INR 1,182 Cr.
- 2
Operating EBITDA (excluding Kasaragod) for Aster DM Healthcare increased 31% YoY to INR 253 Cr in Q4 FY26, with margins improving to 21.7% from 19.3% in Q4 FY25.
- 3
Normalised PAT (excluding Kasaragod) for Aster DM Healthcare rose 45% YoY to INR 153 Cr in Q4 FY26.
- 4
On a combined proforma basis (Aster + QCIL), Q4 FY26 revenues grew by 18% to INR 2,361 Cr, while Operating EBITDA increased by 25% to INR 517 Cr, achieving a margin of 21.9%.
- 5
The merger proposal with Quality Care India Limited received overwhelming shareholder approval, with 96.68% of total votes cast in favor.
- 6
Aster Labs recorded an 18% YoY revenue growth in Q4 FY26, and its Operating EBITDA surged by 181% YoY, with margins improving significantly to 14.7% from 6.2% in Q4 FY25.
- 7
Core Hospital & Clinics business delivered an Operating EBITDA margin of 23.1% in Q4 FY26 (24.3% Ex- Kasargod), with ARPP IP rising 9% YoY to INR 1,25,234.
Management Comments
Dr. Azad Moopen
We are very pleased that the merger of Aster DM Healthcare and Quality Care India Limited (QCIL), in partnership with Blackstone, is progressing towards completion in Q1 FY 2026–27. The overwhelming shareholder support, with 96.68% votes in favour, reflects strong confidence in our vision of building a scaled and integrated healthcare platform. On a proforma basis, Q4 FY26 revenues grew 18% YoY to INR 2,361 Cr, while operating EBITDA increased 25% YoY to INR 517 Cr, supported by strong growth in patient volumes, and continued margin expansion. The combined entity will have a capacity of over 10,623 beds across 28 cities, with an additional pipeline of around 4,445 beds, providing clear visibility to exceed 15,500 beds in the near term, thus . This positions the platform to become one of the top three healthcare providers in India.
Dr. Azad Moopen
Our performance this quarter reflects consistent execution, with revenues growing 18% YoY to INR 1,182 Cr. Excluding the impact of the newly commissioned Kasargod facility, operating EBITDA grew 31% YoY, with margins improving to 21.7%, driven by operating leverage and disciplined cost management.
Informational and educational content only. Not investment advice.